#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Dementia Alzheimer's type Colorectal cancer Ovarian cancer Hepatocellular carcinoma Dermatitis atopic Breast cancer metastatic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Polymyositis Indolent systemic mastocytosis Squamous cell carcinoma of the oral cavity Hodgkin's disease Hereditary optic atrophy Marfan's syndrome Ornithine transcarbamoylase deficiency Eosinophilic granulomatosis with polyangiitis Soft tissue sarcoma Nephroblastoma Infection in an immunocompromised host Drug eruption Red blood cell abnormality Pancreatic carcinoma Cortical dysplasia More trials…

    Learn about Rare Diseases

    Toxic epidermal necrolysis – Basic Information Haemophagocytic lymphohistiocytosis – Diagnostics Hepatoblastoma – Trials in Disease Arterial tortuosity syndrome – Diagnostics Mucopolysaccharidosis III – Treatment Pituitary-dependent Cushing’s syndrome – Basic Information Pelizaeus-Merzbacher disease – Trials in Disease Pleural mesothelioma malignant – Basic Information Cytokine release syndrome – Treatment Hereditary optic atrophy – Life with Disease More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Chlorpromazine Hydrochloride Cariprazine Fenofibrate Balstilimab Molidustat Sodium Flutafuranol (18F) Aluminium Oxide Gsk3858279 SRSD107 Retifanlimab Calcium Chloride Dihydrate Niraparib Parsaclisib Hydrochloride Ovolecithin Romidepsin Dinoprostone Diltiazem Corticosteroids, Plain Imidapril Hydrochloride Carbamazepine More therapies…

    Learn about Your Condition

    Graft versus host disease Endocarditis enterococcal Vaginal infection Insulin resistance Cystic fibrosis lung K-ras gene mutation Porphyria non-acute Eclampsia Femoral hernia Mantle cell lymphoma stage II Huntington's disease Mucosal inflammation Psoriasis Rectal cancer stage III Pharyngeal cancer stage I More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

ABM

  • Evaluation of BIO-101 versus placebo for treating severe sarcopenia in elderly patients with reduced mobility

    Not yet recruiting

    3 1
    Investigated Drugs:
    • 20-HYDROXYECDYSONE
    Belgium

  • Study of Telitacicept compared to placebo in adults with moderate to severe systemic lupus erythematosus

    Not yet recruiting

    3 1 1
    Investigated Diseases:
    • Systemic lupus erythematosus
    Investigated Drugs:
    • Telitacicept
    Bulgaria Czechia France Germany Hungary Poland +1

  • Study of Disitamab Vedotin alone or with Pembrolizumab in patients with locally advanced or metastatic urothelial cancer that expresses HER2

    Not yet recruiting

    2 1 1
    Investigated Diseases:
    • Transitional cell carcinoma
    Investigated Drugs:
    • Disitamab Vedotin
    Belgium France Italy Spain

  • Safety and early effectiveness study of VG801 subretinal injection in patients with ABCA4 mutation-associated retinal dystrophy

    Not yet recruiting

    2 1 1
    Investigated Drugs:
    • VG801-1
    • VG801-2
    Germany

  • Study to evaluate ATI-045 injection compared to placebo in adults with moderate to severe atopic dermatitis

    Not yet recruiting

    2 1
    Investigated Diseases:
    • Dermatitis atopic
    Investigated Drugs:
    • HUMANISED IGG1 KAPPA MONOCLONAL ANTIBODY AGAINST THYMIC STROMAL LYMPHOPOIETIN
    Czechia Germany Poland

  • Study of intraperitoneal fosfomycin, metronidazole and molgramostim treatment in patients with multi-quadrant peritonitis during abdominal surgery

    Not yet recruiting

    2 1 1
    Investigated Drugs:
    • Fosfomycin
    • Molgramostim
    • Metronidazole
    Denmark
Previous Page
1 … 770 771 772 773 774 … 1,657
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!